Business Wire

PREVENA™ Therapy Becomes the First and Only Negative Pressure Medical Device FDA-Indicated to Aid in the Reduction of Superficial Surgical Site Infections (SSIs) in Patients ...

SAN ANTONIO--(BUSINESS WIRE)--KCI, an Acelity Company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s De Novo request for the PREVENA™ Incision Management ...
Business Wire

KCI Expands Surgical Incision Management Offering in Europe

SAN ANTONIO--(BUSINESS WIRE)--KCI, an Acelity Company, today announced the availability of two additional PREVENA™ Therapy offerings in Europe: the PREVENA DUO™ Incision Management System with PEEL & ...
Nasdaq

New Data from PROMISES Study Shows PREVENA™ Incision Management System Significantly Reduces Major Complications and Readmissions Compared to Standard of Care

Research presented at the 30th American Association of Hip and Knee Surgeons Annual Meeting (AAHKS) builds on existing evidence that PREVENA™ Therapy lowers surgical site complications and readmission ...